Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Feb;36(2):245–254. doi: 10.1128/aac.36.2.245

Antiretroviral therapy: reverse transcriptase inhibition.

K J Connolly 1, S M Hammer 1
PMCID: PMC188341  PMID: 1376595

Full text

PDF
245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaudo E., Dalakas M., Shanske S., Moraes C. T., DiMauro S., Schon E. A. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991 Mar 2;337(8740):508–510. doi: 10.1016/0140-6736(91)91294-5. [DOI] [PubMed] [Google Scholar]
  2. Baba M., De Clercq E., Tanaka H., Ubasawa M., Takashima H., Sekiya K., Nitta I., Umezu K., Nakashima H., Mori S. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2356–2360. doi: 10.1073/pnas.88.6.2356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boucher C. A., Tersmette M., Lange J. M., Kellam P., de Goede R. E., Mulder J. W., Darby G., Goudsmit J., Larder B. A. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet. 1990 Sep 8;336(8715):585–590. doi: 10.1016/0140-6736(90)93391-2. [DOI] [PubMed] [Google Scholar]
  4. Bozzette S. A., Richman D. D. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. Am J Med. 1990 May 21;88(5B):24S–26S. doi: 10.1016/0002-9343(90)90418-d. [DOI] [PubMed] [Google Scholar]
  5. Brouwers P., Moss H., Wolters P., Eddy J., Balis F., Poplack D. G., Pizzo P. A. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1990 Dec;117(6):980–985. doi: 10.1016/s0022-3476(05)80150-7. [DOI] [PubMed] [Google Scholar]
  6. Butler K. M., Husson R. N., Balis F. M., Brouwers P., Eddy J., el-Amin D., Gress J., Hawkins M., Jarosinski P., Moss H. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991 Jan 17;324(3):137–144. doi: 10.1056/NEJM199101173240301. [DOI] [PubMed] [Google Scholar]
  7. Carter S. G., Kessler J. A., Rankin C. D. Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 1990 Jun;34(6):1297–1300. doi: 10.1128/aac.34.6.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Collier A. C., Bozzette S., Coombs R. W., Causey D. M., Schoenfeld D. A., Spector S. A., Pettinelli C. B., Davies G., Richman D. D., Leedom J. M. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990 Oct 11;323(15):1015–1021. doi: 10.1056/NEJM199010113231502. [DOI] [PubMed] [Google Scholar]
  9. Connolly K. J., Allan J. D., Fitch H., Jackson-Pope L., McLaren C., Canetta R., Groopman J. E. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med. 1991 Nov;91(5):471–478. doi: 10.1016/0002-9343(91)90182-w. [DOI] [PubMed] [Google Scholar]
  10. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  11. Creagh-Kirk T., Doi P., Andrews E., Nusinoff-Lehrman S., Tilson H., Hoth D., Barry D. W. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988 Nov 25;260(20):3009–3015. [PubMed] [Google Scholar]
  12. Cretton E. M., Schinazi R. F., McClure H. M., Anderson D. C., Sommadossi J. P. Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob Agents Chemother. 1991 May;35(5):801–807. doi: 10.1128/aac.35.5.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dournon E., Matheron S., Rozenbaum W., Gharakhanian S., Michon C., Girard P. M., Perronne C., Salmon D., De Truchis P., Leport C. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet. 1988 Dec 3;2(8623):1297–1302. doi: 10.1016/s0140-6736(88)92903-0. [DOI] [PubMed] [Google Scholar]
  14. Durand E., Le Jeunne C., Hugues F. C. Failure of prophylactic zidovudine after suicidal self-inoculation of HIV-infected blood. N Engl J Med. 1991 Apr 11;324(15):1062–1062. doi: 10.1056/NEJM199104113241513. [DOI] [PubMed] [Google Scholar]
  15. Edwards P., Turner J., Gold J., Cooper D. A. Esophageal ulceration induced by zidovudine. Ann Intern Med. 1990 Jan 1;112(1):65–66. doi: 10.7326/0003-4819-112-1-65. [DOI] [PubMed] [Google Scholar]
  16. Eriksson B. F., Schinazi R. F. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1989 May;33(5):663–669. doi: 10.1128/aac.33.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  18. Fischl M. A., Richman D. D., Causey D. M., Grieco M. H., Bryson Y., Mildvan D., Laskin O. L., Groopman J. E., Volberding P. A., Schooley R. T. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989 Nov 3;262(17):2405–2410. [PubMed] [Google Scholar]
  19. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  20. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  21. Fischl M., Galpin J. E., Levine J. D., Groopman J. E., Henry D. H., Kennedy P., Miles S., Robbins W., Starrett B., Zalusky R. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990 May 24;322(21):1488–1493. doi: 10.1056/NEJM199005243222103. [DOI] [PubMed] [Google Scholar]
  22. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Furth P. A., Kazakis A. M. Nail pigmentation changes associated with azidothymidine (zidovudine). Ann Intern Med. 1987 Sep;107(3):350–350. doi: 10.7326/0003-4819-107-2-350. [DOI] [PubMed] [Google Scholar]
  24. Goldman M. E., Nunberg J. H., O'Brien J. A., Quintero J. C., Schleif W. A., Freund K. F., Gaul S. L., Saari W. S., Wai J. S., Hoffman J. M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6863–6867. doi: 10.1073/pnas.88.15.6863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Greene W. C. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 1991 Jan 31;324(5):308–317. doi: 10.1056/NEJM199101313240506. [DOI] [PubMed] [Google Scholar]
  26. Groopman J. E. Granulocyte-macrophage colony-stimulating factor in human immunodeficiency virus disease. Semin Hematol. 1990 Jul;27(3 Suppl 3):8–14. [PubMed] [Google Scholar]
  27. Helbert M., Robinson D., Peddle B., Forster S., Kocsis A., Jeffries D., Pinching A. J. Acute meningo-encephalitis on dose reduction of zidovudine. Lancet. 1988 Jun 4;1(8597):1249–1252. doi: 10.1016/s0140-6736(88)92072-7. [DOI] [PubMed] [Google Scholar]
  28. Hirsch M. S., Kaplan J. C. Treatment of human immunodeficiency virus infections. Antimicrob Agents Chemother. 1987 Jun;31(6):839–843. doi: 10.1128/aac.31.6.839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Jacobson M. A., Crowe S., Levy J., Aweeka F., Gambertoglio J., McManus N., Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct;158(4):862–865. [PubMed] [Google Scholar]
  30. Japour A. J., Chatis P. A., Eigenrauch H. A., Crumpacker C. S. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3092–3096. doi: 10.1073/pnas.88.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Koshida R., Vrang L., Gilljam G., Harmenberg J., Oberg B., Wahren B. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother. 1989 May;33(5):778–780. doi: 10.1128/aac.33.5.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Koup R. A., Merluzzi V. J., Hargrave K. D., Adams J., Grozinger K., Eckner R. J., Sullivan J. L. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis. 1991 May;163(5):966–970. doi: 10.1093/infdis/163.5.966. [DOI] [PubMed] [Google Scholar]
  33. Lai K. K., Gang D. L., Zawacki J. K., Cooley T. P. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med. 1991 Aug 15;115(4):283–284. doi: 10.7326/0003-4819-115-4-283. [DOI] [PubMed] [Google Scholar]
  34. Lalonde R. G., Deschênes J. G., Seamone C. Zidovudine-induced macular edema. Ann Intern Med. 1991 Feb 15;114(4):297–298. doi: 10.7326/0003-4819-114-4-297. [DOI] [PubMed] [Google Scholar]
  35. Lange J. M., Boucher C. A., Hollak C. E., Wiltink E. H., Reiss P., van Royen E. A., Roos M., Danner S. A., Goudsmit J. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med. 1990 May 10;322(19):1375–1377. doi: 10.1056/NEJM199005103221907. [DOI] [PubMed] [Google Scholar]
  36. Larder B. A., Chesebro B., Richman D. D. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990 Mar;34(3):436–441. doi: 10.1128/aac.34.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  38. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  39. Looke D. F., Grove D. I. Failed prophylactic zidovudine after needlestick injury. Lancet. 1990 May 26;335(8700):1280–1280. doi: 10.1016/0140-6736(90)91343-9. [DOI] [PubMed] [Google Scholar]
  40. McGowan J. J., Tomaszewski J. E., Cradock J., Hoth D., Grieshaber C. K., Broder S., Mitsuya H. Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S513–S521. doi: 10.1093/clinids/12.supplement_5.s513. [DOI] [PubMed] [Google Scholar]
  41. McKinney R. E., Jr, Maha M. A., Connor E. M., Feinberg J., Scott G. B., Wulfsohn M., McIntosh K., Borkowsky W., Modlin J. F., Weintrub P. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991 Apr 11;324(15):1018–1025. doi: 10.1056/NEJM199104113241503. [DOI] [PubMed] [Google Scholar]
  42. McKinney R. E., Jr, Pizzo P. A., Scott G. B., Parks W. P., Maha M. A., Lehrman S. N., Riggs M., Eddy J., Lane B. A., Eppes S. C. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. J Pediatr. 1990 Apr;116(4):640–647. doi: 10.1016/s0022-3476(05)81619-1. [DOI] [PubMed] [Google Scholar]
  43. Merigan T. C., Skowron G., Bozzette S. A., Richman D., Uttamchandani R., Fischl M., Schooley R., Hirsch M., Soo W., Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med. 1989 Feb 1;110(3):189–194. doi: 10.7326/0003-4819-110-3-189. [DOI] [PubMed] [Google Scholar]
  44. Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C. K., Eckner K., Hattox S., Adams J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411–1413. doi: 10.1126/science.1701568. [DOI] [PubMed] [Google Scholar]
  45. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Montaner J. S., Le T., Fanning M., Gelmon K., Tsoukas C., Falutz J., O'Shaughnessy M., Wainberg M. A., Ruedy J. The effect of zidovudine on platelet count in HIV-infected individuals. J Acquir Immune Defic Syndr. 1990;3(6):565–570. [PubMed] [Google Scholar]
  48. Morse G. D., Lechner J. L., Santora J. A., Rozek S. L. Zidovudine update: 1990. DICP. 1990 Jul-Aug;24(7-8):754–760. doi: 10.1177/106002809002400720. [DOI] [PubMed] [Google Scholar]
  49. Nunberg J. H., Schleif W. A., Boots E. J., O'Brien J. A., Quintero J. C., Hoffman J. M., Emini E. A., Goldman M. E. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991 Sep;65(9):4887–4892. doi: 10.1128/jvi.65.9.4887-4892.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Palasanthiran P., Ziegler J. B., Kemp A. S., Ekert H., Jupe D. M., Gatenby P. A., Keller A. J., Smales O. Zidovudine (AZT) therapy in children with HIV infection: the Australian experience. J Paediatr Child Health. 1990 Oct;26(5):257–262. doi: 10.1111/j.1440-1754.1990.tb01067.x. [DOI] [PubMed] [Google Scholar]
  51. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M. J., Breslin H. J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990 Feb 1;343(6257):470–474. doi: 10.1038/343470a0. [DOI] [PubMed] [Google Scholar]
  52. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Gartner S., Popovic M., Hao Z., Gerrard T. L., Wilson Y. A., Johns D. G. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med. 1988 Sep 1;168(3):1111–1125. doi: 10.1084/jem.168.3.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Pialoux G., Youle M., Dupont B., Gazzard B., Cauwenbergh G. F., Stoffels P. A., Davies S., de Saint Martin J., Janssen P. A. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet. 1991 Jul 20;338(8760):140–143. doi: 10.1016/0140-6736(91)90135-c. [DOI] [PubMed] [Google Scholar]
  54. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  55. Pluda J. M., Yarchoan R., Jaffe E. S., Feuerstein I. M., Solomon D., Steinberg S. M., Wyvill K. M., Raubitschek A., Katz D., Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med. 1990 Aug 15;113(4):276–282. doi: 10.7326/0003-4819-113-4-276. [DOI] [PubMed] [Google Scholar]
  56. Pluda J. M., Yarchoan R., Smith P. D., McAtee N., Shay L. E., Oette D., Maha M., Wahl S. M., Myers C. E., Broder S. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood. 1990 Aug 1;76(3):463–472. [PubMed] [Google Scholar]
  57. Richman D. D., Andrews J. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am J Med. 1988 Aug 29;85(2A):208–213. [PubMed] [Google Scholar]
  58. Richman D. D. Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1. Antimicrob Agents Chemother. 1987 Dec;31(12):1879–1881. doi: 10.1128/aac.31.12.1879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  60. Richman D. D., Grimes J. M., Lagakos S. W. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3(8):743–746. [PubMed] [Google Scholar]
  61. Richman D. D. Zidovudine resistance of human immunodeficiency virus. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S507–S512. doi: 10.1093/clinids/12.supplement_5.s507. [DOI] [PubMed] [Google Scholar]
  62. Richman D., Rosenthal A. S., Skoog M., Eckner R. J., Chou T. C., Sabo J. P., Merluzzi V. J. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother. 1991 Feb;35(2):305–308. doi: 10.1128/aac.35.2.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Rooke R., Parniak M. A., Tremblay M., Soudeyns H., Li X. G., Gao Q., Yao X. J., Wainberg M. A. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother. 1991 May;35(5):988–991. doi: 10.1128/aac.35.5.988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Rozencweig M., McLaren C., Beltangady M., Ritter J., Canetta R., Schacter L., Kelley S., Nicaise C., Smaldone L., Dunkle L. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S570–S575. doi: 10.1093/clinids/12.supplement_5.s570. [DOI] [PubMed] [Google Scholar]
  65. Sandstrom E. G., Kaplan J. C., Byington R. E., Hirsch M. S. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet. 1985 Jun 29;1(8444):1480–1482. doi: 10.1016/s0140-6736(85)92255-x. [DOI] [PubMed] [Google Scholar]
  66. Sattler F. R., Ko R., Antoniskis D., Shields M., Cohen J., Nicoloff J., Leedom J., Koda R. Acetaminophen does not impair clearance of zidovudine. Ann Intern Med. 1991 Jun 1;114(11):937–940. doi: 10.7326/0003-4819-114-11-937. [DOI] [PubMed] [Google Scholar]
  67. Schinazi R. F., Sommadossi J. P., Saalmann V., Cannon D. L., Xie M. Y., Hart G. C., Smith G. A., Hahn E. F. Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1990 Jun;34(6):1061–1067. doi: 10.1128/aac.34.6.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Schmitt F. A., Bigley J. W., McKinnis R., Logue P. E., Evans R. W., Drucker J. L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988 Dec 15;319(24):1573–1578. doi: 10.1056/NEJM198812153192404. [DOI] [PubMed] [Google Scholar]
  69. Shirasaka T., Murakami K., Ford H., Jr, Kelley J. A., Yoshioka H., Kojima E., Aoki S., Broder S., Mitsuya H. Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9426–9430. doi: 10.1073/pnas.87.23.9426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Stambuk D., Youle M., Hawkins D., Farthing C., Shanson D., Farmer R., Lawrence A., Gazzard B. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study. Q J Med. 1989 Feb;70(262):161–174. [PubMed] [Google Scholar]
  71. Steffe E. M., King J. H., Inciardi J. F., Flynn N. F., Goldstein E., Tonjes T. S., Benet L. Z. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immune Defic Syndr. 1990;3(7):691–694. [PubMed] [Google Scholar]
  72. Swanson C. E., Cooper D. A. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group. AIDS. 1990 Aug;4(8):749–757. doi: 10.1097/00002030-199008000-00006. [DOI] [PubMed] [Google Scholar]
  73. Tan C. K., Civil R., Mian A. M., So A. G., Downey K. M. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry. 1991 May 21;30(20):4831–4835. doi: 10.1021/bi00234a001. [DOI] [PubMed] [Google Scholar]
  74. Tanaka H., Baba M., Hayakawa H., Sakamaki T., Miyasaka T., Ubasawa M., Takashima H., Sekiya K., Nitta I., Shigeta S. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem. 1991 Jan;34(1):349–357. doi: 10.1021/jm00105a055. [DOI] [PubMed] [Google Scholar]
  75. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]
  76. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  77. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]
  78. Yarchoan R., Mitsuya H., Thomas R. V., Pluda J. M., Hartman N. R., Perno C. F., Marczyk K. S., Allain J. P., Johns D. G., Broder S. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science. 1989 Jul 28;245(4916):412–415. doi: 10.1126/science.2502840. [DOI] [PubMed] [Google Scholar]
  79. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]
  80. Yarchoan R., Pluda J. M., Thomas R. V., Mitsuya H., Brouwers P., Wyvill K. M., Hartman N., Johns D. G., Broder S. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet. 1990 Sep 1;336(8714):526–529. doi: 10.1016/0140-6736(90)92085-v. [DOI] [PubMed] [Google Scholar]
  81. Yarchoan R., Thomas R. V., Grafman J., Wichman A., Dalakas M., McAtee N., Berg G., Fischl M., Perno C. F., Klecker R. W. Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol. 1988;23 (Suppl):S82–S87. doi: 10.1002/ana.410230722. [DOI] [PubMed] [Google Scholar]
  82. Zimmerman T. P., Mahony W. B., Prus K. L. 3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem. 1987 Apr 25;262(12):5748–5754. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES